Single-cell RNA-seq reveals novel immune-associated biomarkers for predicting prognosis in AML patients with RUNX1::RUNX1T1
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.111178 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Xue-Ping Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; State Key Laboratory of Oncology in South Chin…. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sun Yat-sen University Cancer Center, Basic and Applied Basic Research Foundation of Guangdong Province, Natural Science Foundation of Shanghai Municipality.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) with t(8;21)(q22;q22);(RUNX1::RUNX1T1) is highly heterogeneous and malignant. It has a relapse rate of nearly 40 %, resulting in clinical resistance or refractoriness to chemotherapy. Immune cells, particularly CD4(+) T and CD8(+) T lymphocytes, have been discovered to be dysfunctional in this condition, and functional recovery shows promising efficiency in preclinical trials. Here, with single-cell transcriptomic data from de novo AML patients with RUNX1::RUNX1T1 and at various stages following disease progression, we investigated the genes correlated with T-cell proliferation and activation. In leukemia cells, ADA, AHCY, GPN3 and LTBR were markedly highly expressed compared to those in T-cell at diagnosis, and they tended to increase with disease progression. Additionally, we discovered that AHCY was an effective biomarker to predict the overall survival as well as relapse-free survival of AML patients with RUNX1::RUNX1T1. The correlation of AHCY with infiltrated immune cells and immune checkpoints was also investigated. AML cohorts from two other independent studies, TCGA LAML (n = 145) and the GEO dataset (n = 104), also demonstrated an inferior outcome for AML patients with high AHCY expression. In conclusion, our research revealed that AHCY might function as a novel indicator to predict the prognosis and efficiency of T-cell proliferation and activation in AML patients with RUNX1::RUNX1T1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-s…
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, C…
- Department of Hematology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; Department of Medical Oncology, Sun Yat-sen U…
Förderung
- Sun Yat-sen University Cancer Center
- Basic and Applied Basic Research Foundation of Guangdong Province
- Natural Science Foundation of Shanghai Municipality
- National Natural Science Foundation of China
- Shanghai Jiao Tong University
- China Postdoctoral Science Foundation
Zitieren
APA
Li, X. P., Dai, Y., Zhang, W. N., Pan, M. M., Mao, J., Zhao, B., Jiang, L., & Gao, Y. (2023). Single-cell RNA-seq reveals novel immune-associated biomarkers for predicting prognosis in AML patients with RUNX1::RUNX1T1. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.111178
Vancouver
Li XP, Dai Y, Zhang WN, Pan MM, Mao J, Zhao B, et al. Single-cell RNA-seq reveals novel immune-associated biomarkers for predicting prognosis in AML patients with RUNX1::RUNX1T1. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.111178
BibTeX
@article{Li2023,
author = {Li, Xue-Ping and Dai, Yuting and Zhang, Wei-Na and Pan, Meng-Meng and Mao, Jiaying and Zhao, Baitian and Jiang, Lu and Gao, Yan},
title = {Single-cell RNA-seq reveals novel immune-associated biomarkers for predicting prognosis in AML patients with RUNX1::RUNX1T1},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.111178}
}
EUVIMED